Microarray profiling of breast carcinoma has identified five distinct subtypes of tumors (luminal A, luminal B, normal breast-like, human epidermal growth factor receptor 2 (HER2)-overexpressing, and basal-like) that are associated with different clinical outcomes [4–7]. This evidence concerns the gene ERBB2 and breast carcinoma.